Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases
- PMID: 18690987
- DOI: 10.2174/157488608784529260
Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases
Abstract
Infections are relevant complications that cause morbidity in solid organ transplantation and autoimmune diseases. Infection represents a leading single cause of death in these patients. Identification of patients at risk for development of infections and specific intervention to decrease infection risk might lead to better outcomes, though one needs first to evaluate the presence of risk factors for infection. Underlying disease itself, activity of the disease, presence of co-morbidities, transplantation procedures along with immunosuppressive and immunomodulatory therapies may be associated with an increased risk of infections. Among host factors, there are no reliable immunological markers to predict infections. Immune monitoring (assessment of immunocompetence) to estimate the risk of infection has so far not been performed routinely, with the only exception of neutrophil counts, tuberculin skin testing and serological evaluation of donor and recipients of transplants for anti-cytomegalovirus IgG antibodies. However, alterations of specific and non specific humoral and cellular immunity may be associated with a higher risk of infection among immunosuppressed patients. We review studies that have been designed to assess immune monitoring for prediction of infections in patients with selected solid organ transplantations and systemic autoimmune diseases.
Similar articles
-
Immunological risk factors for infection after immunosuppressive and biologic therapies.Expert Rev Anti Infect Ther. 2011 Apr;9(4):405-13. doi: 10.1586/eri.10.178. Expert Rev Anti Infect Ther. 2011. PMID: 21504398 Review.
-
Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.Clin Immunol. 2007 Jun;123(3):235-43. doi: 10.1016/j.clim.2007.01.001. Epub 2007 Feb 27. Clin Immunol. 2007. PMID: 17329169 Free PMC article. Review.
-
Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.Curr Opin Organ Transplant. 2008 Dec;13(6):575-80. doi: 10.1097/MOT.0b013e3283186b80. Curr Opin Organ Transplant. 2008. PMID: 19060545 Review.
-
Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection.Transpl Infect Dis. 2008 Dec;10(6):396-402. doi: 10.1111/j.1399-3062.2008.00329.x. Epub 2008 Jul 24. Transpl Infect Dis. 2008. PMID: 18657086
-
Can immune biomarkers predict infections in solid organ transplant recipients? A review of current evidence.Transplant Rev (Orlando). 2019 Apr;33(2):87-98. doi: 10.1016/j.trre.2018.10.001. Epub 2018 Oct 9. Transplant Rev (Orlando). 2019. PMID: 30551846 Review.
Cited by
-
Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.PLoS One. 2013 Nov 19;8(11):e78699. doi: 10.1371/journal.pone.0078699. eCollection 2013. PLoS One. 2013. PMID: 24260127 Free PMC article. Clinical Trial.
-
Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study.Stem Cell Res Ther. 2018 Nov 14;9(1):312. doi: 10.1186/s13287-018-1053-4. Stem Cell Res Ther. 2018. PMID: 30428931 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical